Lyra Therapeutics, Inc.
LYRA
Price:
$0.2727
Market Cap:
$17.85M
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its ...[Read more]
Industry
Biotechnology
IPO Date
2020-05-01
Stock Exchange
NASDAQ
Ticker
LYRA
The PE Ratio as of September 2024 (TTM) for Lyra Therapeutics, Inc. (LYRA) is -0.18
According to Lyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.18. This represents a change of -94.49% compared to the average of -3.26 of the last 4 quarters.
Lyra Therapeutics, Inc. (LYRA) Historical PE Ratio (quarterly & annually)
How has LYRA PE Ratio performed in the past?
The mean historical PE Ratio of Lyra Therapeutics, Inc. over the last ten years is -7.64. The current -0.18 PE Ratio has changed 135.52% with respect to the historical average. Over the past ten years (40 quarters), LYRA's PE Ratio was at its highest in in the June 2024 quarter at -0.10. The PE Ratio was at its lowest in in the March 2020 quarter at -13.57.
Average
-7.64
Median
-4.30
Minimum
-19.29
Maximum
-1.34
Lyra Therapeutics, Inc. (LYRA) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Lyra Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 142.42%
Maximum Annual PE Ratio = -1.34
Minimum Annual Increase = -70.20%
Minimum Annual PE Ratio = -19.29
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -4.16 | 142.42% |
| 2022 | -1.72 | 28.65% |
| 2021 | -1.34 | -69.95% |
| 2020 | -4.44 | -70.20% |
| 2019 | -14.91 | -22.73% |
Lyra Therapeutics, Inc. (LYRA) Average PE Ratio
How has LYRA PE Ratio performed in the past?
The current PE Ratio of Lyra Therapeutics, Inc. (LYRA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.41
5-year avg
-5.31
10-year avg
-7.64
Lyra Therapeutics, Inc. (LYRA) PE Ratio vs. Peers
How is LYRA’s PE Ratio compared to its peers?
Lyra Therapeutics, Inc.’s PE Ratio is less than CytomX Therapeutics, Inc. (9.19), greater than Assembly Biosciences, Inc. (-2.10), greater than Achilles Therapeutics plc (-0.45), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Instil Bio, Inc. (-0.78), greater than NextCure, Inc. (-0.65), less than Spero Therapeutics, Inc. (4.06), greater than Nuvation Bio Inc. (-1.34), greater than Cullinan Oncology, Inc. (-6.96), greater than Bolt Biotherapeutics, Inc. (-0.37), greater than Day One Biopharmaceuticals, Inc. (-7.39), greater than Autolus Therapeutics plc (-4.55),
| Company | PE Ratio | Market cap |
|---|---|---|
| 9.19 | $93.74M | |
| -2.10 | $107.81M | |
| -0.45 | $29.58M | |
| -0.98 | $8.20M | |
| -0.78 | $92.68M | |
| -0.65 | $39.73M | |
| 4.06 | $71.07M | |
| -1.34 | $692.60M | |
| -6.96 | $1.04B | |
| -0.37 | $24.78M | |
| -7.39 | $1.25B | |
| -4.55 | $1.07B |
Build a custom stock screener for Lyra Therapeutics, Inc. (LYRA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Lyra Therapeutics, Inc. (LYRA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Lyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Lyra Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Lyra Therapeutics, Inc. (LYRA)?
What is the highest PE Ratio for Lyra Therapeutics, Inc. (LYRA)?
What is the 3-year average PE Ratio for Lyra Therapeutics, Inc. (LYRA)?
What is the 5-year average PE Ratio for Lyra Therapeutics, Inc. (LYRA)?
How does the current PE Ratio for Lyra Therapeutics, Inc. (LYRA) compare to its historical average?